The Application of the Union of Insulin Detemir with Metformin & Nateglinide in Treating Poorly Glycaemic Controlled Type 2 Diabetes Mellitus Out-patient

Huai‐Ning Wu

2013-01-01

Abstract:Objective To compare the effect of two insulin therapic schemes in treating type 2 diabetes mellitus patients. Both schemes use metformin and nateglinide to control poor glycaemic. One scheme adds injecting insulin detemir per day, the other one adds injecting isophane insulin per day. Methods 78 patients of poorly glycaemic controlled type 2 diabetes mellitus were divided into two groups randomly. 40 cases of the treatment group, average age(46 ±9.8)years, 25 males and 15 females, were given combined insulin detemir therapies; 38 cases of the control group, average age 45±8.9, 22 males and16 females were given combined isophane insulin. The treatment lasted for 12 weeks. Results After treatment, for the treatment group, the fasting glucose level decreased from(9.9±1.3)mmol/L to(6.9±0.9)mmol/L, postprandial glycated hemoglobin level from(12.2±2.2)mmol/L to(8.4±0.7)mmol/L, hypoglycemia from(8.8±0.5)% to(6.6±0.9)%; For the control group, the fasting glucose level decreased from(9.8±1.2)mmol/L to(7.0±0.8)mmol/L,postprandial glycated hemoglobin level from(12.5±2.3)mmol/L to(8.5±0.6)mmol/L, hypoglycemia from(8.7±0.6)% to(6.7±0.8)%. After treatment of 12 weeks, there were significant statistical differences for the fasting blood glucose level, 2-hr postprandial blood glucose level and glycated hemoglobin value(HbA1 c) before and after treatment(P0.05). there were 5 cases of hypoglycemia for the treatment group, 11 cases for the contrast group; 2 cases of expulsion for treatment group(3/40,7.5%), 5 cases for contrast group(5/38, 13.8%). The body mass index of contrast groups is up, but no statistical difference with that of treatment group. Conclusions The scheme of uniting insulin detemir with metformin and nateglinide has advantages of improving the achievement rate of glycaemic control, little impact on patients' weight, low incidence of hypoglycemia, safe usage, convenience and good clients' compliance.